Hear what our multidisciplinary, pan-Canadian expert panel has to say about chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) in the Hallway Huddle. Each 5–10-minute video in this series features one of our experts presenting the latest on screening, guidelines, residual risk, and novel treatments for the management of CKD in T2D.
.
When and why should patients with T2D have their UACR tested?
Navdeep Tangri, MD, PhD, FRCPC
What do the guidelines say about managing CKD in T2D?
Alice Y.Y. Cheng, MD, FRCPC
What are the key differences between steroidal MRAs and nonsteroidal MRAs?
Daniel Ngui, BScPT, PT, MD, CCFP, FCFP
For which patients should novel nonsteroidal MRAs be considered?
Normand Proulx, MD, FRCP(C)
What data supports the use of novel nonsteroidal MRAs in patients already on an SGLT2 inhibitor?
Normand Proulx, MD, FRCP(C)
When and how should potassium levels be monitored and managed in patients on MRAs?
Louise Moist, MD, MSC, CCPE, FRCPC
What is residual risk and why does it matter in patients with CKD and T2D?
Navdeep Tangri, MD, PhD, FRCPC
Measures of albuminuria and why UACR is the gold standard for measuring cardiorenal risk?
Jordan Weinstein, MD, FRCPC
UPDATE: What do the guidelines say about managing CKD in T2D?
Sara Stafford, MDCM, FRCPC
What are the MOAs of the new therapies and how do they complement each other?
Normand Proulx, MD, FRCP(C)
What to know about initiating and monitoring patients on finerenone?
Jordan Weinstein, MD, FRCPC
What to tell patients about adding another treatment, like finerenone to their regimen?
Shelley Zieroth, MD, FCCS, FHFSA (hon), FESC, FACC, FHFA, FRCPC
Nephrologist, CISSS de l'Outaouais
Pavillon de Hull
Part-time Lecturer, McGill University
Gatineau, QC